WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 39.10
-0.14 (-0.36%)
Jul 24, 2026, 4:08 PM HKT
WuXi Biologics Stock Forecast
Stock Price Forecast
According to 26 analysts polled by S&P Global, WuXi Biologics stock has a consensus rating of "Buy" and an average price target of $47.00. The average 1-year stock price forecast is 20.20% higher than the current stock price, while the lowest is $30.59 (-21.76%) and the highest is $78.43 (+100.59%).
Price Target: $47.00 (+20.20%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for WuXi Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 16 | 17 | 17 | 17 |
| Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Hold | 4 | 5 | 4 | 4 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 27 | 25 | 25 | 25 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst SDIC Securities No rating | SDIC Securities | Buy Maintains $47.44 | Buy | Maintains | $47.44 | +21.33% | Jul 17, 2026 |
Unknown Analyst CLSA No rating | CLSA | Buy Maintains $51.90 | Buy | Maintains | $51.90 | +32.74% | Jul 10, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $50.00 | Buy | Maintains | $50.00 | +27.88% | Jul 9, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $49.30 → $51.10 | Buy | Maintains | $49.30 → $51.10 | +30.69% | Jul 2, 2026 |
Unknown Analyst Guotai Haitong No rating | Guotai Haitong | Buy Maintains $54.49 | Buy | Maintains | $54.49 | +39.36% | Jun 9, 2026 |
Financial Forecast
Revenue This Year
25.27B
from 21.79B
Increased by 15.96%
Revenue Next Year
29.70B
from 25.27B
Increased by 17.53%
EPS This Year
1.43
from 1.33
Increased by 7.30%
EPS Next Year
1.73
from 1.43
Increased by 21.45%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.